Investigating the role of sTREM in outcomes after thrombectomy for stroke
Soluble Soluble Triggering Receptors Expressed on Myeloid Cells (sTREM) Predict Outcomes in Stroke Patients Receiving Endovascular Thrombectomy
This study is trying to see if certain proteins in the blood can help predict how well people recover after a procedure to remove a blood clot from their brain during a stroke.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University Academic / other |
| Locations | 1 site (Xuzhou, Jiangsu) |
| Trial ID | NCT06545591 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the prognostic significance of soluble triggering receptors expressed on myeloid cells (sTREM1 and sTREM2) in patients with acute ischemic stroke who undergo endovascular thrombectomy (EVT). By analyzing blood samples taken before and after the procedure, the study seeks to establish a correlation between sTREM levels and functional outcomes at three months post-stroke. The research will also include non-stroke controls and patients who did not receive EVT to provide a comprehensive understanding of sTREM's role in stroke recovery.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with acute large vessel occlusion who are scheduled to receive endovascular treatment within 24 hours of symptom onset.
Not a fit: Patients who are unable to provide blood samples or those who refuse informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify biomarkers that predict recovery outcomes for stroke patients undergoing thrombectomy.
How similar studies have performed: While the role of sTREM in stroke outcomes is being explored, this specific approach appears to be novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18 years old. * Patients with acute large vessel occlusion within 24 hours of onset who will receive endovascular treatment. Exclusion Criteria: * Impossibility of getting a blood sample. * Impossibility of performing the test (Invalid results). * Refusal to provide the informed consent by the patient/relative.
Where this trial is running
Xuzhou, Jiangsu
- Department of Neurology — Xuzhou, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Xingzhi Wang, MD
- Email: wxz1220@126.com
- Phone: 0086-13852000759
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.